Persistent, recurrent, or metastatic cervical cancer
Clinical trials for Persistent, recurrent, or metastatic cervical cancer explained in plain language.
Never miss a new study
Get alerted when new Persistent, recurrent, or metastatic cervical cancer trials appear
Sign up with your email to follow new studies for Persistent, recurrent, or metastatic cervical cancer, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Can an immunotherapy boost give advanced cervical cancer patients more time?
Disease control Recruiting nowResearchers are testing whether adding an experimental immunotherapy drug called GLS-010 to standard platinum-based chemotherapy, with or without bevacizumab, helps women with persistent, recurrent, or metastatic cervical cancer live longer. The trial enrolls about 424 women aged…
Matched conditions: PERSISTENT, RECURRENT, OR METASTATIC CERVICAL CANCER
Phase 3 • Sponsor: Guangzhou Gloria Biosciences Co., Ltd. • Aim: Disease control
Last updated Sep 18, 2026 00:00 UTC
-
Can cervical cancer patients stop immunotherapy early? new study investigates
Disease control Recruiting nowThis study follows 261 people with persistent, recurrent, or metastatic cervical cancer who are taking pembrolizumab (Keytruda) with or without bevacizumab (Avastin). Some participants may choose to stop pembrolizumab early if their tumor shrinks or disappears, while others conti…
Matched conditions: PERSISTENT, RECURRENT, OR METASTATIC CERVICAL CANCER
Phase 4 • Sponsor: University Medical Center Groningen • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC